Splenectomy Considerations in Immune Thrombocytopenia
Indications and Timing
- The American Society of Hematology recommends splenectomy for adult ITP patients who have failed first-line corticosteroid therapy, with a Grade 1B recommendation (strong recommendation, moderate quality evidence) 1
- Splenectomy should be delayed for at least 12 months from ITP diagnosis to allow for spontaneous remissions or therapy-induced responses, unless severe disease is present 2
- The American Society of Hematology gives splenectomy a strong recommendation for patients who have failed corticosteroid therapy, with moderate quality evidence 1
Alternative Therapies
- Thrombopoietin Receptor Agonists (TPO-RAs) may be considered for patients at risk of bleeding who have failed one line of therapy, achieving platelet responses in 70-80% of patients 3
- Rituximab may be considered for patients at risk of bleeding who have failed one line of therapy, allowing further delay of splenectomy while attempting medical management 1, 2
Preoperative Requirements
- Polyvalent pneumococcal vaccine, meningococcal C conjugate vaccine, and Haemophilus influenzae b (Hib) vaccine must be administered at least 4 weeks before surgery to protect against encapsulated organisms 4
Expected Outcomes
- Splenectomy provides an initial response rate of 80-85%, with sustained long-term responses occurring in 60-66% of patients 3, 5
- Up to 30% of initial responders will relapse, typically within the first 2 years post-splenectomy 3, 5
Long-Term Risks
- Patients who undergo splenectomy have a 3-fold increased risk of septicemia, a 4.5-fold increased risk of pulmonary embolism, and a 2.7-fold increased risk of venous thromboembolism 5
- These risks persist for more than 10 years after surgery 3